Gut bacteria linked to liver cancer risk?
We link liver cancer to viral hepatitis, alcohol, and metabolic disease. Yet a 12-cohort study reveals that gut barrier dysfunction, detectable years before diagnosis via bacterial translocation markers, independently predicts liver cancer. This gut-liver axis mechanism reshapes our understanding of hepatocarcinogenesis.
Lay public section
Find here your dedicated section
Sources
This article is based on scientific information
About this article
Liver cancer development has been primarily attributed to well-established risk factors including viral hepatitis, excessive alcohol consumption, and metabolic conditions. However, a groundbreaking nested case-control study published in the International Journal of Cancer examined 867 liver cancer cases and 867 matched controls across 12 United States cohorts, revealing that immunological markers of (sidenote: Bacterial translocation The passage of viable bacteria or bacterial products such as lipopolysaccharide and flagellin across the intestinal barrier into systemic circulation. When gut barrier function is compromised, bacterial translocation triggers immune activation and chronic inflammation that may contribute to hepatocarcinogenesis. ) , measured an average of 12 years before diagnosis, are independently associated with liver cancer risk1.
The gut barrier under scrutiny
The gut barrier serves a critical dual function, allowing nutrient absorption while preventing translocation of harmful bacterial products into systemic circulation. Researchers from multiple institutions measured pre-diagnostic serum concentrations of (sidenote: Lipopolysaccharide-binding protein An acute-phase protein primarily synthesized by hepatocytes that binds to lipopolysaccharide from gram-negative bacteria to form an LPS-LBP complex. ) , (sidenote: Soluble CD14 A co-receptor protein that recognizes the LPS-LBP complex and facilitates immune signaling to trigger inflammatory responses. ) , and antibodies against lipopolysaccharide and flagellin. These markers reflect the body's response to gut-derived bacterial products that have breached the intestinal barrier.
LBP, an acute-phase protein synthesized primarily by hepatocytes, binds to lipopolysaccharide from gram-negative bacteria and forms complexes recognized by soluble CD14, triggering inflammatory cascades. The most striking finding was that LBP concentrations showed the strongest association with liver cancer risk, with an odds ratio of 1.48 per doubling in concentration. Anti-flagellin IgA and IgG, anti-lipopolysaccharide IgG, and soluble CD14 were also positively associated with risk.
Hepatocellular carcinoma versus cholangiocarcinoma
When analyses were stratified by liver cancer subtype, a critical distinction emerged. LBP concentrations were positively associated with hepatocellular carcinoma with an odds ratio of 1.77 per doubling, but showed no association with intrahepatic cholangiocarcinoma with an odds ratio of 0.67. This finding suggests potential specificity in the bacterial translocation pathway for hepatocellular carcinoma development.
Animal models have previously demonstrated that lipopolysaccharide accumulation activates (sidenote: Toll-like receptor 4 A pattern recognition receptor that recognizes lipopolysaccharide and initiates inflammatory signaling pathways. Animal studies have shown that TLR4 activation by bacterial lipopolysaccharide promotes hepatic inflammation and accelerates hepatocellular carcinoma development, providing a mechanistic link between bacterial translocation and liver cancer. ) signaling, promoting hepatic inflammation and tumor formation. The prospective nature of this study, with biomarkers measured years before diagnosis, suggests that LBP elevation represents an early etiological factor in hepatocarcinogenesis rather than merely a consequence of underlying liver disease. Associations were generally consistent across subgroups and remained significant even after excluding participants with hepatitis B or C infection.
The findings highlight the (sidenote: Gut-liver axis The bidirectional relationship between the gastrointestinal tract and the liver, mediated by the portal venous system that carries nutrients and bacterial products from the gut to the liver. ) as a modifiable pathway in liver cancer development, necessitating further investigation into interventions that maintain gut barrier integrity.
